Right Turn: On the right track to health and prosperity

Author: Stacey Johnson, 05/27/16

The subway map is a popular metaphor for showing how to get from point A to point B with many stops along the way. It can be simple, with only a few intersecting lines of tracks – Toronto’s (shockingly inadequate) two-line system comes to mind – or complicated, like Beijing and New York City, to…Read more

The out of this world story behind Endonovo’s regenerative medicine technology

Author: Paul Krzyzanowski, 05/25/16

A few weeks ago, I came across an interesting story about a stem cell company with a peculiar patenting strategy. As I looked into it further, I realized I’d stumbled into a complicated corporate plot that became more incredible with every turn. Endonovo Therapeutics is pursuing patents around molecules produced from adult stem cells which,…Read more

Right Turn: Making science fun and relatable

Author: Stacey Johnson, 05/20/16

A popular marketing strategy is to reach (insert demographic) “where they live.” Science Genius appears to have taken that concept to heart when it comes to kids and science. Science Genius, launched in December 2012 by Christopher Emdin, the musician GZA and the website Rap Genius, began in New York City (NYC) to encourage teens…Read more

Here’s a (r)evolutionary idea: using stem cells to study differences in species

Author: Holly Wobma, 05/16/16

At the crossroad of developmental biology and tissue engineering, there is a group of scientists trying to delicately coax stem cells down a specific path. In the metaphoric sense, they are most interested in how the nature of their cells evolves over time. But what if stem cells could teach us something about evolution itself?…Read more

Right Turn: Resources for scientists

Author: Stacey Johnson, 05/13/16

I’ve read enough PhD Comics to understand that being a scientist is hard. (I work with them too, but I’m saving those stories for my tell-all autobiography.) Recently I stumbled upon* what I believe could be a useful resource for scientists to make their lives a little easier, and it made me wonder what other…Read more

Understanding immortality, one slice at a time

Author: Guest, 05/10/16

Jovana Drinjakovic is a science writer with a background in cell and developmental biology. After completing her PhD in Cambridge (the old one) and a postdoc at the Hospital for Sick Children in Toronto, Jovana decided to switch gears and enrolled in a journalism course at the University of Toronto’s Munk School of Global Affairs….Read more

Right Turn: Henrietta Lacks immortalized on film

Author: Stacey Johnson, 05/06/16

Arguably one of the most popular science books ever written is heading to the big screen. Tech Insider calls The Immortal Life of Henrietta Lacks “the most important science book of our time.” And with Oprah Winfrey cast as Henrietta’s daughter, you will be hard pressed to avoid hearing about this upcoming movie. (Here’s a…Read more

The race to develop senescent cell clearance therapies

Author: Nick Dragojlovic, 05/03/16

A growing focus of biomedical research and regenerative medicine is the effort to target the aging process itself, by either slowing or reversing the accumulation of cellular and molecular damage that drives age-related functional decline. The goal is to develop new treatments for age-related chronic diseases, which are the leading cause of death in the…Read more

Right Turn: Throw away that scalpel; here comes the “biopen”

Author: Stacey Johnson, 04/29/16

Jennifer Hicks at Forbes has written about a handheld surgical device that can draw stem cells to repair cartilage so that the damaged cartilage can heal itself with its own cells. How cool is that?! The ARC Centre of Excellence for Electromaterials Science in Melbourne, Australia, has produced the biopen. It is still at the…Read more

Update from the Clinic: March

Author: Mark Curtis, 04/28/16

Welcome to your Update from the Clinic for the month of March. Undoubtedly the big news in March came from Vericel, which saw its stock double after reporting positive topline results from its Phase 2b study in heart failure. There were also some first dosings and clinical study starts. A study of Vericel’s (VCEL) ixmyelocel-T…Read more